0000000000586810

AUTHOR

Amparo Pastor

showing 5 related works from this author

Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease

1998

Human cytomegalovirus (HCMV)-specific antibody responses in HIV-1 infected individuals either with or without HCMV end-organ disease were examined to determine the whether development of HCMV disease was associated with a particular deficit in the antibody response. Antiwhole HCMV, anti-glycoprotein B (gB), and neutralizing antibody levels were higher in HIV-1 infected individuals than in healthy immunocompetent subjects, particularly in patients with AIDS either with or without HCMV-associated disease. Irrespective of location and spread of HCMV disease, patients who had received anti-HCMV therapy prior to sampling exhibited significantly higher anti-gB and neutralizing antibody titers tha…

AdultMaleHuman cytomegalovirusAdolescentvirusesCytomegalovirusBiologyAntibodies ViralAntiviral AgentsViral Envelope ProteinsNeutralization TestsBetaherpesvirinaeVirologyImmunopathologymedicineHumansViremiaFluorescent Antibody Technique IndirectNeutralizing antibodyAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAntibody titervirus diseasesbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationVirologyCD4 Lymphocyte CountInfectious DiseasesImmunoglobulin GCytomegalovirus InfectionsImmunologyHIV-1biology.proteinFemaleViral diseaseAntibodyViral loadJournal of Medical Virology
researchProduct

Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.

2015

Lung transplant patients present important variability in immunosuppressant blood concentrations during the first months after transplantation. Pharmacogenetics could explain part of this interindividual variability. We evaluated SNPs in genes that have previously shown correlations in other kinds of solid organ transplantation, namely ABCB1 and CYP3A5 genes with tacrolimus (Tac) and ABCC2, UGT1A9 and SLCO1B1 genes with mycophenolic acid (MPA), during the first six months after lung transplantation (51 patients). The genotype was correlated to the trough blood drug concentrations corrected for dose and body weight (C0/Dc). The ABCB1 variant in rs1045642 was associated with significantly hig…

Adultmedicine.medical_specialtyATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatment<i>P</i>-glycoproteinSingle-nucleotide polymorphismPharmacologyP-glycoproteinGastroenterologyPolymorphism Single NucleotideCatalysisMycophenolic acidTacrolimusArticlelcsh:ChemistryInorganic ChemistryInternal medicineBlood drugmedicinelung transplantationLung transplantationCytochrome P-450 CYP3AHumansPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopybiologyOrganic ChemistryGeneral MedicineMiddle AgedMycophenolic AcidTacrolimusMultidrug Resistance-Associated Protein 2Computer Science ApplicationsTransplantationlcsh:Biology (General)lcsh:QD1-999Pharmacogeneticsbiology.proteinMultidrug Resistance-Associated ProteinsSLCO1B1PharmacogeneticsImmunosuppressive Agentsmedicine.drugInternational journal of molecular sciences
researchProduct

Genotype and Allele Frequencies of Drug-Metabolizing Enzymes and Drug Transporter Genes Affecting Immunosuppressants in the Spanish White Population

2013

Interpatient variability in drug response can be widely explained by genetically determined differences in metabolizing enzymes, drug transporters, and drug targets, leading to different pharmacokinetic and/or pharmacodynamic behaviors of drugs. Genetic variations affect or do not affect drug responses depending on their influence on protein activity and the relevance of such proteins in the pathway of the drug. Also, the frequency of such genetic variations differs among populations, so the clinical relevance of a specific variation is not the same in all of them. In this study, a panel of 33 single nucleotide polymorphisms in 14 different genes (ABCB1, ABCC2, ABCG2, CYP2B6, CYP2C19, CYP2C…

GenotypeCYP2B6Nod2 Signaling Adaptor ProteinOrganic Anion TransportersSingle-nucleotide polymorphismCYP2C19PharmacologyPolymorphism Single NucleotideWhite PeopleCytochrome P-450 Enzyme SystemGene FrequencyGenetic variationGenotypeHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1GlucuronosyltransferaseAllele frequencyCYP2C9Methylenetetrahydrofolate Reductase (NADPH2)PharmacologyGeneticsbiologyMethyltransferasesMultidrug Resistance-Associated Protein 2Tissue DonorsTransplant RecipientsSpainInactivation MetabolicUDP-Glucuronosyltransferase 1A9biology.proteinSLCO1B1Immunosuppressive AgentsTherapeutic Drug Monitoring
researchProduct

Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.

2018

Post-transplant lymphoproliferative disorders (PTLD) are a rare complication after both solid organ (SOT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this single center retrospective study, we compared clinical, biological, and histological features, and outcomes of PTLD after both types of transplant. We identified 82 PTLD (61 after SOT and 21 after allo-HSCT). The presence of B symptoms, Waldeyer ring, spleen, central nervous system, and liver involvement, and advanced Ann-Arbor stage were more frequent in allo-HSCT recipients. PTLD had an earlier onset in allo-HSCT than in SOT cohort (4 vs. 64 months, p  .0001). PTLD was EBV-positive in 100% of allo-HSCT, in co…

AdultGraft RejectionMaleCancer ResearchPathologymedicine.medical_specialtyEpstein-Barr Virus InfectionsHerpesvirus 4 HumanTransplantation ConditioningAdolescentmedicine.medical_treatmentLymphoproliferative disordersHematopoietic stem cell transplantationmedicine.disease_causeSingle Center03 medical and health sciencesYoung Adult0302 clinical medicineEpstein–Barr virus Solid organ transplantation hematopoietic stem cell transplantation immunosuppression post-transplant lymphoproliferative disordershemic and lymphatic diseasesmedicineHumansTransplantation HomologousRetrospective Studiesbusiness.industryHematopoietic Stem Cell TransplantationImmunosuppressionHematologyOrgan TransplantationMiddle Agedmedicine.diseaseEpstein–Barr virusSurvival AnalysisPost transplantLymphoproliferative Disorderssurgical procedures operativeOncology030220 oncology & carcinogenesisFemaleVirus ActivationSolid organLymph NodesbusinessComplication030215 immunology
researchProduct

Tuberculosis Following Lung Transplantation. A 27-Year Spanish Multicenter Experience. Incidence, Presentation, Prevention and Treatment with Rifampi…

2020

Abstract Background Tuberculosis (TB) represents a diagnostic and therapeutic challenge for solid organ transplant recipients, particularly after lung transplant (LT). Our aim was to determine the impact of TB in LT patients in Spain, considering prevalence, clinical presentation, prevention and therapeutic management. In addition, differences in outcome between rifampicin (RIF) versus non-RIF containing regimens were analyzed. Methods Multicenter, observational retrospective study, including all cases of TB diagnosed in recipients after LT, in five pulmonary transplant units in Spain, between January 1990 and December 2017. Results Among 2962 LT recipients, 45 cases of TB were diagnosed, r…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyTuberculosismedicine.medical_treatment03 medical and health sciences0302 clinical medicineInternal medicineHumansTuberculosisMedicineLung transplantationRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyGeneral Medicinebacterial infections and mycosesmedicine.diseaseCalcineurinRegimen030228 respiratory systemSpainTrough levelRifampinbusinessRifampicinLung Transplantationmedicine.drugArchivos de Bronconeumología
researchProduct